Fosun Marks Ninth Year at CIIE, Guo Guangchang Calls for Bringing More Innovation to China and Taking Chinese Innovation Global

The healthcare showcase includes Chinese regulatory milestones and Saudi breakthrough therapy designation for FUMAINING.

Rhea-AI Summary

Fosun (FOSUF) returned to the China International Import Expo, showcasing healthcare products with overseas member companies and global partners. Intuitive Surgical presented da Vinci 5 in China for the first time. Fosun plans to sign partnership agreements during the expo.

Fosun Pharma's disclosed regulatory milestones include China approval of injectable Akynzeo in 2026 and WANTILE's China approval and national reimbursement inclusion in 2025. The da Vinci SP surgical system entered China's special review procedure for innovative medical devices. HANSIZHUANG is available in more than 50 countries and regions, while HANQUYOU has marketing approval in more than 50. FUMAINING received Breakthrough Therapy Designation in Saudi Arabia; the company expects this to accelerate approval and commercialization there.

Positive

• Minor pointInjectable Akynzeo received approval in China in 2026.
• Minor pointWANTILE received China approval in February 2025 and national reimbursement inclusion later that year.
• Minor pointDa Vinci SP entered China's special review procedure for innovative medical devices.
• Minor pointDa Vinci SP was included in the Hong Kong and Macau Medicine and Equipment Connect catalog this year.
• Minor pointIon System received marketing approval in China in 2024.

4 minor points

• Minor pointHANQUYOU has secured marketing approval in more than 50 countries and regions.
• Minor pointHANLIKANG has received approval in several Latin American markets.
• Minor point. Forward-looking: it has not happened yet and may not happen.FUMAINING received Saudi Breakthrough Therapy Designation; Fosun expects accelerated regulatory approval and commercialization.
• Minor point. Forward-looking: it has not happened yet and may not happen.Fosun Pharma is accelerating domestic localization of Akynzeo.

Negative

• None.

Key Figures

Yi Kai Da treatment reach: More than 1,500 patients Initial trial patient status: More than 8 years cancer-free Exablate Neuro treatment reach: Over 30,000 patients +4 more

Yi Kai Da treatment reach

More than 1,500 patients

Patients with relapsed or refractory lymphoma treated

Initial trial patient status

More than 8 years cancer-free

Initial clinical trial patient receiving Yi Kai Da

Exablate Neuro treatment reach

Over 30,000 patients

Treatment worldwide

Exablate Neuro center reach

More than 210 medical centers

Worldwide

Artesunate supply

More than 460 million vials

Cumulative supply worldwide by the end of the first half of 2026

Severe malaria patients reached

More than 92 million patients

Patients saved by artesunate for injection, as stated in the article

Akynzeo injectable approval

2026

Approval in China

Key Terms

car-t cell therapy, gmp certifications, breakthrough therapy designation, anti-pd-1 monoclonal antibody

4 terms

car-t cell therapy medical

"China's first approved CAR-T cell therapy"

A therapy that takes a patient’s own immune cells, reprograms them in a lab to recognize and attack specific disease cells, then returns them to the body—think of training and equipping a guard dog to find a particular intruder. Investors care because these treatments can offer dramatic clinical benefits, carry high development and manufacturing costs, and create new, often lucrative markets if they receive regulatory approval and payer support.

gmp certifications regulatory

"production lines that have obtained GMP certifications"

GMP certifications are formal approvals showing a manufacturer follows Good Manufacturing Practice standards, which ensure products are made consistently, safely, and meet quality controls. Investors care because these certifications lower the risk of product recalls, regulatory penalties, and reputational damage—think of them like a thorough safety inspection for a factory that signals more reliable operations and steadier future revenue.

breakthrough therapy designation regulatory

"was granted Breakthrough Therapy Designation (BTD)"

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

anti-pd-1 monoclonal antibody medical

"the world's first anti-PD-1 monoclonal antibody approved"

A laboratory-produced monoclonal antibody that binds the programmed cell death protein 1 (PD-1) receptor on immune cells and blocks its interaction with PD-1 ligands (PD-L1/PD-L2). By preventing this inhibitory signaling, the antibody releases a brake on T‑cell activity so the immune system can better recognize and attack targeted cells; it is administered like other therapeutic antibodies and can cause immune-related inflammatory side effects because it increases immune activation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HONG KONG, Nov. 5, 2026 /PRNewswire/ -- On 5 November 2026, the 9th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center (Shanghai). This year's expo has convened participants from 162 countries, regions, and international organizations, featuring more than 4,100 corporate exhibitors and a record-breaking number of new product debuts. As a nine-year CIIE participant, Fosun has joined forces with its overseas member companies and global partners to present its latest achievements in innovative drugs, advanced medical devices, and health management at the Fosun Pharma booth (booth no.: 2.1C4-01) in the Medical Equipment and Healthcare Products Exhibition Area. The exhibits cover core therapeutic areas including oncology, immunology and inflammation, and neurodegenerative diseases.

Guo Guangchang, Chairman of Fosun International, remarked: "Having participated in all nine editions of the CIIE, Fosun has witnessed the platform become increasingly dynamic and open, generating a steady stream of innovation. For Fosun, the CIIE is far more than a six-day expo. It serves as an annual test of our global industrial and innovation capabilities. Over the past nine years, we have helped bring world-class technologies to China, converting 'exhibits' into commercial 'products' while helping overseas partners transition from 'exhibitors' to 'investors'. At the same time, the CIIE has accelerated the global expansion of Fosun's innovations."

"Whether introducing the da Vinci surgical systems, the Magnetic Resonance-guided Focused Ultrasound (MRgFUS) system, and Ongentys to China, or delivering HANSIZHUANG, HANQUYOU, and artesunate to patients worldwide, our underlying approach remains identical: combining global resources with China's capabilities. As China embarks on its 15th Five-Year Plan, Fosun will leverage its established innovation and globalization capabilities. Together with our global partners, we will bring more high-quality innovations to China and scale Chinese breakthroughs in global markets to benefit more patients worldwide," Guo Guangchang added.

da Vinci 5 Makes China Debut Alongside Cutting-Edge Technologies

The Fosun Pharma booth features cutting-edge medical technologies and innovative products from around the world. Commemorating the 20th anniversary of introducing its da Vinci surgical systems to China, Fosun's partner Intuitive Surgical is presenting the next-generation da Vinci 5 system for the first time in China, designed for robotic-assisted thoracic and abdominal procedures. Meanwhile, Sweden-based Breas Medical is debuting its new Breas Apto respiratory mask for the Chinese market.

For nine years, Fosun has accelerated the transition of innovative technologies from exhibition debuts to commercial launches. In 2017, Fosun Pharma partnered with Intuitive Surgical, a global leader in robotic-assisted surgery, to establish Intuitive Fosun, a joint venture based in Shanghai. The da Vinci Xi surgical system debuted at the inaugural CIIE in 2018 and achieved commercial launch in China the following year, successfully transforming "exhibits" into commercial "products". The Ion Robotic Bronchoscopy (Ion System) followed a similar trajectory. First showcased at the CIIE in 2019, it received marketing approval in China in 2024, extending the use of minimally invasive robotic technology beyond surgery to the diagnosis and treatment of lung diseases. This year, the da Vinci SP surgical system was included in the catalog under the "Hong Kong and Macau Medicine and Equipment Connect" scheme. It was also admitted into the Special Review Procedure for Innovative Medical Devices by the National Medical Products Administration (NMPA), paving the way to benefit more patients.

Intuitive Fosun's portfolio now includes two platforms: the da Vinci surgical systems and the Ion System. With 33 training centers established across China, it has trained more than 23,000 doctors and built a clinical solutions team of nearly 200 professionals to provide hospitals with ongoing support in using the systems.

From Exhibition to Clinical Practice: Making Innovation More Accessible and Affordable

The evolution of da Vinci surgical systems in China—from being an exhibit to a commercial product, and from imported technology to advanced local manufacturing—demonstrates how the CIIE's impact extends well beyond the expo itself. It also reflects Fosun's growing ability to adapt innovations for local needs and bring them into commercial production, accelerating the translation of global medical advances into clinical benefits for patients across China.

This year, Fosun Pharma is showcasing further advances in innovative drugs and medical devices across oncology, immunology and inflammation, and central nervous system diseases. Several products that made their initial debuts at previous editions of the CIIE have since transitioned into essential treatment options for patients.

Fosun Pharma introduced Akynzeo (netupitant and palonosetron hydrochloride capsules), the world's first fixed-dose combination antiemetic targeting two distinct pathways, to China and is now accelerating its domestic localization. Following its inclusion in the National Reimbursement Drug List (NRDL) in 2023, Akynzeo's injectable formulation received approval in China in 2026. Yi Kai Da (ejilunsai injection), China's first approved CAR-T cell therapy, is now available across a network of over 190 treatment centers spanning 29 provinces, autonomous regions, and municipalities nationwide. More than 1,500 patients with relapsed or refractory lymphoma have received the therapy, with the initial clinical trial patient remaining cancer-free for more than eight years. Meanwhile, WANTILE (tenapanor hydrochloride tablets), the world's first phosphate absorption inhibitor, received approval in China in February 2025 and was incorporated into the NRDL later that year.

In neurodegenerative diseases, Fosun Pharma is showcasing Exablate Neuro, a MRgFUS system that has treated over 30,000 patients across more than 210 medical centers worldwide. Unlike conventional brain surgery, the procedure requires no skull opening, implants or general anesthesia. It offers a new treatment option for patients with medication-refractory essential tremor or tremor-dominant Parkinson's disease. The showcase also includes Ongentys (opicapone capsules), a new treatment for Parkinson's disease approved in more than 40 countries and regions. It became available in the Boao Lecheng International Medical Tourism Pilot Zone in 2024. To address unmet clinical needs in conditions such as Alzheimer's and Parkinson's diseases, Fosun is actively building an integrated ecosystem combining diagnosis with advanced therapeutics.

From an innovation's CIIE debut to regulatory approval, commercial launch and local production, the ultimate value of innovation lies in patient accessibility. By expanding reach through a combination of national medical insurance, commercial health insurance and municipal-level government-backed supplemental insurance program (Huiminbao), Fosun is working to make innovative treatments remain both accessible and affordable, translating CIIE opportunities into tangible patient benefits.

Driving Global Expansion of Innovative Drugs and Deepening Global Partnerships

As a platform bridging global innovations with the Chinese market and advancing domestic breakthroughs worldwide, the CIIE continues to deepen two-way collaboration. During this year's expo, Fosun will sign strategic agreements and participate in high-level forums to expand its global partnership network, bring together resources and expertise, and translate innovation into practical applications.

This global expansion is underpinned by a supply chain network adhering to international quality standards. Fosun Pharma has 65 pharmaceutical manufacturing sites and production lines that have obtained GMP certifications from major overseas markets or WHO prequalification. This enables the company to maintain a reliable and steady supply of medicines to key markets worldwide, including China, the United States, Europe, India, Africa and Southeast Asia.

Building on its global strengths, Fosun is accelerating the global expansion of its innovative drugs, unlocking their value in markets worldwide. By the end of the first half of 2026, Fosun Pharma had cumulatively supplied more than 460 million vials of artesunate for injection worldwide, saving more than 92 million patients with severe malaria. Its independently developed HANSIZHUANG (serplulimab) is the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer, and the first anti-PD-1 monoclonal antibody approved for perioperative treatment of gastric cancer. It is now available in more than 50 countries and regions. HANQUYOU (trastuzumab), the first China-developed monoclonal antibody biosimilar to receive approval in China, the European Union and the United States, has secured marketing approval in more than 50 countries and regions. HANLIKANG (rituximab), China's first biosimilar, has also received approval in several Latin American markets. Meanwhile, FUMAINING (luvometinib tablets), a highly selective MEK1/2 inhibitor, was granted Breakthrough Therapy Designation (BTD) by the Saudi Food and Drug Authority (SFDA), which is expected to accelerate its regulatory approval and commercialization in Saudi Arabia.

By integrating product supply, localized manufacturing, regulatory approval, and commercial collaboration, Fosun Pharma is leveraging its global presence to deliver long-term value to patients worldwide. These efforts reflect Fosun's "innovation + globalization" strategy in action across its pharmaceutical and healthcare businesses.

"The value of the CIIE goes beyond the products showcased and agreements signed during the expo. Its lasting value lies in how many of these innovations ultimately become accessible diagnostic and therapeutic options for patients worldwide. Transforming exhibits into products and bringing those products to patients have guided our participation across all nine editions of the CIIE and will remain a long-term priority for Fosun," said Guo Guangchang.

View original content:https://www.prnewswire.com/news-releases/fosun-marks-ninth-year-at-ciie-guo-guangchang-calls-for-bringing-more-innovation-to-china-and-taking-chinese-innovation-global-302930491.html

SOURCE Fosun

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Saudi breakthrough therapy designation mean for Fosun Pharma's FUMAINING?

Fosun expects FUMAINING's Breakthrough Therapy Designation from the Saudi Food and Drug Authority to accelerate regulatory approval and commercialization in Saudi Arabia. The designation applies to luvometinib tablets, a MEK1/2 inhibitor.

What overseas manufacturing qualifications does Fosun Pharma report?

Fosun Pharma has 65 pharmaceutical manufacturing sites and production lines with Good Manufacturing Practice certifications from major overseas markets or World Health Organization prequalification.